drugset / Trial / NCT02106650

Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

NCT02106650

NaSingle-groupOpen-labelPrevention

Summary

This study is to evaluate the effect of leucovorin in preventing or reducing Folotyn-related Grade 2 or higher oral mucositis.

Timeline

Start
2014-07
Primary completion
2018-10
Completion
2019-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule 25 mg Oral
Background Pralatrexate Other / unclassified 30 mg/m2 Intravenous
Background Vitamin B12 Other / unclassified 1 mg Intramuscular
Background folic acid Other / unclassified 1 mg Oral